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The battle for COVID-19 vaccines highlights the 
need for a new global governance mechanism
To the Editor—Although the rapid 
development of several vaccines against 
COVID-19 is an unparalleled scientific 
accomplishment, one made possible through 
the collaboration of researchers, industry 
and funding bodies, the absence of a system 
that secures equitable access to vaccines 
has uncovered deep fissures in the global 
governance systems for health, as noted in a 
recent Nature Medicine Editorial1.
For example, advance purchase 
agreements for vaccines against COVID-19 
have favored affluent countries, allowing 
them to secure 150–500% of their predicted 
needs2, while many citizens of low-and 
middle-income countries (LMICs) will 
remain unvaccinated until 2024.
Additionally, the power of patent-holders 
and pharmaceutical companies to place 
conditions on the use of vaccines prices out 
access for LMICs, and bilateral purchasing 
deals are rarely disclosed.
By affording priority on the basis 
of economic or political power, today’s 
discourse clearly deviates from previous 
ethical and public-health principles of 
maximizing lives or life-years saved, and 
the sentiment that “people’s entitlement to 
lifesaving resources should not depend on 
nationality”3.
The COVID-19 pandemic has tested 
wealthy nations’ commitments to Agenda 
2030 (ref. 4) and to ‘leaving no one behind’ 
at the same time that it has revealed 
democratic deficits, institutional rigidity, 
weak accountability systems, and inadequate 
policy space that protects health-governance 
systems from economic goals5.
Thus, the as-yet-limited support for the 
vaccine-sharing and allocation principles 
of the COVAX initiative6 may be a sign 
not only of a moral catastrophe, to quote 
the director-general of the World Health 
Organization (WHO), but also of inadequate 
global accountability mechanisms that 
exposes the consequences of commercial 
determinants of health.
The ongoing battle for scarce vaccines 
against COVID-19 also highlights the lack 
of legally binding mechanisms that hold 
market actors accountable for failing to 
act for the public good, and the absence of 
global mechanisms for coordinating the 
pooling and sharing of resources.
In a recent example, high-income 
countries blocked an effort to enable  
timely, affordable access to products for  
the ‘prevention, containment or treatment’ 
of COVID-19, when India and South  
Africa proposed that the World Trade 
Organization temporarily suspend Trade 
Related Aspects of Intellectual Property 
Rights rules7.
Already in 2019, a Lancet Commission 
recommended increased utilization of 
legal mechanisms to advance global health 
through justice systems8 and to harness 
the power of law to promote global health 
and sustainable development, calling upon 
governments, the WHO and United Nations 
organizations to make necessary legal 
reforms to translate vision into action.
The current crisis is a salient opportunity 
for strengthening the global response to 
upcoming pandemics. With the belief that 
vaccines against COVID-19 are a global 
common good and that allocation should 
be based on need, we make the following 
recommendations.
First, a global legal framework is needed 
to regulate the commercial determinants 
of health and to secure universal fair access 
to essential technologies and vaccine 
production. This may be financed through 
existing alliances (such as COVAX, or Gavi, 
the Vaccine Alliance) or by new G7 or G20 
standing funds for vaccine development  
and allocation9. In times of emergency,  
the World Trade Organization should also 
grant temporary waivers for Trade Related 
Aspects of Intellectual Property Rights 
rules for governments to produce their 
own vaccines or, if necessary, to exercise 
compulsory licensing powers for a third 
party to produce a patented technology. 
Ideally, perceived legal risk could facilitate 
the negotiation of purchase transparency, 
voluntary licensing arrangements and  
patent sharing while committing the 
industry to global justice.
Second, to strengthen crisis 
preparedness4 and make the response 
less blunt and more evidence-based, 
coordinated and effective, the existing 
gaps in infrastructure, technology and 
information must be reduced. The WHO 
warns that lockdown-induced disruption 
(e.g., of childhood immunization and 
essential care) could cause greater death and 
suffering than COVID-19 itself10. As LMICs 
embark on an unprecedented vaccination 
scale-up, substantial investment is needed 
to prevent redistribution of scarce health 
personnel that further undermines routine 
immunization. Future plans must have a 
clear health-systems dimension and must 
include social mobilization and strategies for 
fighting vaccine misinformation7.
Third, as shown by COVID-19, updated 
global governance mechanisms are needed 
that better reflect the contemporary 
geopolitical order and truly encourage 
international collaboration across sectors, 
through political and legal solutions rooted 
in commitments to justice and shared global 
responsibility5,8. We call for a 21st-century 
Bretton Woods–type conference, similar to 
that of 1944, when states met to improve 
global economic interaction, secure 
peace and provide assistance to countries 
devastated by World War II, which resulted 
in new global governance structures such 
as the International Monetary Fund and the 
World Bank.
Using the dynamics of one acute  
crisis to build resilience against the next 
could also serve a greater good in line 
with the growing notion of the United 
Nations Security Council that health, 
poverty mitigation, security and peace are 
interlinked. ❐
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